logo
  • Home
  • News
Menu

GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A

Home / Stock Analysis / GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A
Article feature image

GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A

12 Aug Stock Analysis

YONGIN, South Korea–(BUSINESS WIRE)–GC Pharma (006280.KS) today announced the approval of GreenGene F (Beroctocog alfa)

Click here to view the original article.

Tags:
Business Wire, Global
Facebook Google+ Twitter Pinterest
  Previous
Next  

Related Posts

1585186556238.jpeg
+

A Closer Look at Confluent (CFLT) Valuation After Recent 19% Share Price Gain

02 Nov Stock Analysis
0902-Q1920Total20Markets20photos20and20gif_CC8.jpg
+

BIDU Quantitative Stock Analysis | Nasdaq

02 Nov Stock Analysis

recent post

  • 69070febdd872a669480e700_69070fe946b207df17b31503_lastImage.png

    Ethereum’s Price Surge: Navigating the Future

    Nov 02 2025
  • hack-crack.jpg

    Crypto Hacks Plunge 85% in October

    Nov 02 2025
  • 6907078d3c375e729d4b4e9a_6907078b66873343ef3d2e52_lastImage.png

    Adapting to Binance’s New Leverage Tiers:

    Nov 02 2025
  • 1585186556238.jpeg

    A Closer Look at Confluent (CFLT)

    Nov 02 2025
  • 690704967eb79d9a33134748_6907049264b38c18a51c4bf1_lastImage.png

    Ethereum’s Shift: Regulatory Changes and the

    Nov 02 2025

Categories

  • Business
  • Crypto News
  • Investing Strategy
  • People
  • Stock Analysis

©2019.  All Rights Reserved.